New anticonvulsant candidates prevent P-glycoprotein (P-gp) overexpression in a pharmacoresistant seizure model in mice.


Journal

Epilepsy & behavior : E&B
ISSN: 1525-5069
Titre abrégé: Epilepsy Behav
Pays: United States
ID NLM: 100892858

Informations de publication

Date de publication:
08 2021
Historique:
received: 05 05 2019
revised: 17 07 2019
accepted: 19 07 2019
pubmed: 20 8 2019
medline: 12 8 2021
entrez: 18 8 2019
Statut: ppublish

Résumé

Despite the approval of a considerable number of last generation antiepileptic drugs (AEDs) (only in the last decade, six drugs have gained Food and Drug Administration approval), the global figures of seizure control have seemingly not improved, and available AED can still be regarded as symptomatic treatments. Fresh thinking in AEDs drug discovery, including the development of drugs with novel mechanisms of action, is required to achieve truly innovative antiepileptic medications. The transporter hypothesis proposes that inadequate penetration of AEDs across the blood-brain barrier, caused by increased expression of efflux transporters such as P-glycoprotein (P-gp), contributes to drug-resistant epilepsy. Neuroinflammation due to high levels of glutamate has been identified as one of the causes of P-gp upregulation, and several studies in animal models of epilepsy suggest that antiinflammatory drugs might prevent P-gp overexpression and, thus, avoid the development of refractory epilepsy. We have applied ligand-based in silico screening to select compounds that exert dual anticonvulsant and antiinflammatory effects. Five of the hits were tested in animal models of seizure, with protective effects. Later, two of them (sebacic acid (SA) and gamma-decanolactone) were submitted to the recently described MP23 model of drug-resistant seizures. All in all, SA displayed the best profile, showing activity in the maximal electroshock seizure (MES) and pentylenetetrazol (PTZ) seizure models, and reversing resistance to phenytoin (PHT) and decreasing the P-gp upregulation in the MP23 model. Furthermore, pretreatment with SA in the pilocarpine status epilepticus (SE) model resulted in decreased histamine release in comparison with nontreated animals. This is the first report of the use of the MP23 model to screen for novel anticonvulsant compounds that may avoid the development of P-gp-related drug resistance.

Identifiants

pubmed: 31420290
pii: S1525-5050(19)30441-X
doi: 10.1016/j.yebeh.2019.106451
pii:
doi:

Substances chimiques

ATP Binding Cassette Transporter, Subfamily B 0
Anticonvulsants 0
Pharmaceutical Preparations 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

106451

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Andrea Verónica Enrique (AV)

Laboratorio de Investigación y Desarrollo de Bioactivos (LIDeB), Departamento de Ciencias Biologicas, Facultad de Ciencias Exactas, Universidad Nacional de La Plata (UNLP), 47 y115, La Plata B1900BJW, Argentina.

Mauricio Emiliano Di Ianni (ME)

Laboratorio de Investigación y Desarrollo de Bioactivos (LIDeB), Departamento de Ciencias Biologicas, Facultad de Ciencias Exactas, Universidad Nacional de La Plata (UNLP), 47 y115, La Plata B1900BJW, Argentina.

Sofía Goicoechea (S)

Laboratorio de Investigación y Desarrollo de Bioactivos (LIDeB), Departamento de Ciencias Biologicas, Facultad de Ciencias Exactas, Universidad Nacional de La Plata (UNLP), 47 y115, La Plata B1900BJW, Argentina.

Alberto Lazarowski (A)

Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Facultad de Farmacia y Bioquímica (FFyB), Universidad de Buenos Aires (UBA,) Junín 956, C1113AAD CABA, Argentina.

María Guadalupe Valle-Dorado (MG)

Department of Pharmacobiology, Center for Research and Advanced Studies (CINVESTAV), Mexico City, Mexico.

Juan José López Costa (JJL)

Departamento de Biología Celular, Histología, Embriología y Genética, Facultad de Medicina, Universidad de Buenos Aires (UBA) / Instituto de Biología Celular y Neurociencia "Prof. E. De Robertis" (IBCN), CONICET-Universidad de Buenos Aires, Paraguay 2155, C1121ABG, Buenos Aires, Argentina.

Luisa Rocha (L)

Department of Pharmacobiology, Center for Research and Advanced Studies (CINVESTAV), Mexico City, Mexico.

Elena Girardi (E)

Departamento de Biología Celular, Histología, Embriología y Genética, Facultad de Medicina, Universidad de Buenos Aires (UBA) / Instituto de Biología Celular y Neurociencia "Prof. E. De Robertis" (IBCN), CONICET-Universidad de Buenos Aires, Paraguay 2155, C1121ABG, Buenos Aires, Argentina.

Alan Talevi (A)

Laboratorio de Investigación y Desarrollo de Bioactivos (LIDeB), Departamento de Ciencias Biologicas, Facultad de Ciencias Exactas, Universidad Nacional de La Plata (UNLP), 47 y115, La Plata B1900BJW, Argentina. Electronic address: atalevi@biol.unlp.edu.ar.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Humans Pharmaceutical Preparations Drug Utilization Prescription Drugs
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Classifications MeSH